Survodutide
BI 456906 · Boehringer Ingelheim dual agonist
Popular for:Weight loss, MASH/NASH liver disease, dual GLP-1/glucagon agonist
24
Registered Trials
7
Trial Publications
60
PubMed References
Phase III
Evidence Level
Overview
Survodutide is a dual GLP-1/glucagon receptor agonist developed by Boehringer Ingelheim, currently in Phase III clinical trials for obesity and metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH). The short version: people usually care about it for weight loss, mash/nash liver disease, dual glp-1/glucagon agonist, but the strength of the evidence depends heavily on indication and study type.
Survodutide is a dual GLP-1/glucagon receptor agonist developed by Boehringer Ingelheim, currently in Phase III clinical trials for obesity and metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH). It represents a different dual-agonist approach than tirzepatide — instead of GLP-1/GIP, survodutide combines GLP-1 with glucagon receptor activation.
The glucagon component is significant: while it may seem counterintuitive to activate a hormone that raises blood sugar, glucagon receptor activation increases hepatic fat oxidation and energy expenditure. Phase II results showed up to 19% weight loss and significant liver fat reduction, making it a promising candidate for both obesity and fatty liver disease.
Research Snapshot
What the evidence says
Phase IIISurvodutide currently shows 24 registered trials from ClinicalTrials.gov, 7 PubMed trial publications (6 RCT-tagged), and 60 PubMed references matching the stored source query. Treat PubMed references as literature surface area, not a count of clinical trials.
Known vs uncertain
Known signals
- 24 registered trials are tracked from ClinicalTrials.gov intervention records.
- 7 PubMed clinical-trial publications are indexed.
- 6 PubMed randomized controlled trial publications are indexed.
- 60 PubMed references are tracked separately from trial counts and can include animal, in-vitro, review, mechanism, or clinical records.
Open questions
- Evidence strength may vary by indication, route, formulation, and population.
- Public anecdotes can highlight interest or concern but do not establish clinical efficacy.
- Regulatory status and compounding access can change independently from the research literature.
Mechanism of Action
Survodutide activates both GLP-1 and glucagon receptors.
Key Research Benefits
Clinical Evidence Summary
Research Pipeline
24
Registered Trials
7
Trial Publications
6
RCT Publications
60
PubMed References
Registered trials are ClinicalTrials.gov intervention records. Trial publications are PubMed records tagged as clinical trials or randomized controlled trials. PubMed references are broader source-query matches and can include animal studies, in-vitro work, reviews, mechanism papers, and trial publications.
24
Registered trials
7
Trial publications
6
RCT publications
60
PubMed references
31
Reviews
7
Meta-analyses
Registered trials source
Jun 1, 2026
Survodutide
Uses the exact compound name as a ClinicalTrials.gov intervention query.
View sourceInvestigational — Phase III clinical trials ongoing (Boehringer Ingelheim). Not available outside clinical trials. Potential regulatory submission expected 2027-2028.
Key PubMed References
60 PubMed references · showing top 25 by relevance
View all on PubMedBaseline characteristics in the SYNCHRONIZE™-2 randomized phase 3 trial of survodutide, a glucagon receptor/GLP-1 receptor dual agonist, for obesity in people with type 2 diabetes.
Wharton S, le Roux CW, Bozkurt B, et al. · Diabetes, obesity & metabolism · 2026
PMID: 41216778Novel GLP-1-based Medications for Type 2 Diabetes and Obesity.
Son JW, le Roux CW, Blüher M, et al. · Endocrine reviews · 2026
PMID: 41054801A review of survodutide: a new dual acting agonist.
Yathindra MR, Bhattacharjee A, Pundir N, et al. · Minerva endocrinology · 2026
PMID: 41855048Weight management treatment in obesity.
Rubio-Herrera MA, Mera-Carreiro S · Medicina clinica · 2025
PMID: 40865172Emerging pharmacotherapies for obesity: A systematic review.
Kokkorakis M, Chakhtoura M, Rhayem C, et al. · Pharmacological reviews · 2025
PMID: 39952695Anecdotes & Sentiment
This section summarizes what people are talking about in public sources. It can be useful for spotting questions, hype cycles, and recurring concerns, but it is separate from the evidence sections above.
No curated public-discussion themes are live for Survodutide yet.
Side Effects & Safety
- Nausea and vomiting (dose-dependent, common with GLP-1 class) - Diarrhea - Decreased appetite - Potential blood sugar elevation from glucagon component - Full safety profile not yet established
Known Interactions
No curated interaction entry is live for Survodutide yet.
Until the interaction table is fully populated, use the interaction checker and related peptides below to explore adjacent compounds and likely research pairings.
Comparison Pages
Comparison pages
AllNo comparison page is linked yet.
Frequently Asked Questions
Research Disclaimer
This page is for research and educational purposes only. The information presented is based on published scientific literature and does not constitute medical advice, diagnosis, or treatment recommendations. Regulatory status can vary by compound, formulation, indication, and jurisdiction. Check official labeling, registry records, and qualified professional guidance before making any health-related decision. The studies referenced are linked to their original PubMed sources for verification.